Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

Phase 3 Recruiting 328 enrolled Jiangxi Qingfeng Pharmaceutical Co. Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.

Timeline

Start: 2024-11-11
Primary completion: 2025-12-30
Completion: 2025-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GP681	Unknown	40 mg	Oral

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

Summary

Timeline

Drugs

Indications